| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 12/19/2013 | WO2013186563A2 Factor viii sequences |
| 12/19/2013 | WO2013186234A1 Process for producing a composition containing active follistatin |
| 12/19/2013 | WO2013186138A1 Preparation comprising insulin, nicotinamide and arginine |
| 12/19/2013 | WO2013185575A1 Small-molecule-polypeptide conjugate for inhibiting hiv infection |
| 12/19/2013 | WO2013185572A1 αO-SUPERFAMILY CONOTOXIN PEPTIDE, PHARMACEUTICAL COMPOSITION AND USE THEREOF |
| 12/19/2013 | WO2013185552A1 Dual-signal independent chimeric antigen receptor and use thereof |
| 12/19/2013 | WO2013185187A1 Gastrin-releasing peptide receptor-based methods for the treatment of stereotypies, social behavior deficits, and compulsive behaviors associated with neuropsychiatry and neurodevelopmental disorders and pharmaceutical composition containing grp |
| 12/19/2013 | WO2013185178A1 Nanoemulsions |
| 12/19/2013 | WO2013160291A3 Archease as rna ligase complex member |
| 12/19/2013 | WO2013152120A3 Compositions and methods for promoting intestinal stem cell function |
| 12/19/2013 | WO2013138338A3 Methods for treating tissue damage associated with ischemia with apoliporotein d |
| 12/19/2013 | WO2013138259A3 Polypeptides for treating and/or limiting influenza infection |
| 12/19/2013 | WO2013106273A3 Peptides and methods of using same |
| 12/19/2013 | WO2013056122A8 Engineered outer domain (eod) of hiv gp120 and mutants thereof |
| 12/19/2013 | WO2012122059A9 Hydrogen bond surrogate macrocycles as modulators of ras |
| 12/19/2013 | US20130338338 Alpha-conotoxin peptides |
| 12/19/2013 | US20130338084 Hydrogel compositions |
| 12/19/2013 | US20130338083 Methods of providing therapeutic effects using cyclosporin components |
| 12/19/2013 | US20130338082 Methods of providing therapeutic effects using cyclosporin components |
| 12/19/2013 | US20130338081 Iap antagonists |
| 12/19/2013 | US20130338080 Compositions and methods for treating an activated b-cell diffuse large b-cell lymphoma |
| 12/19/2013 | US20130338079 Treatment of primary and metastatic carcinoma |
| 12/19/2013 | US20130338073 Durable haemostatic scaffold |
| 12/19/2013 | US20130338072 Methods for treating organs |
| 12/19/2013 | US20130338071 GLP-1 Agonist and Cardiovascular Complications |
| 12/19/2013 | US20130338070 Fgf-9 variants and methods of use thereof |
| 12/19/2013 | US20130338069 Preparation of a Therapeutic Composition |
| 12/19/2013 | US20130338063 Methods and Compositions for the Treatment of Gastrointestinal Disorders |
| 12/19/2013 | US20130338062 Hcv protease inhibitors and uses thereof |
| 12/19/2013 | US20130337549 Materials and methods for nerve grafting |
| 12/19/2013 | US20130337096 Chewable vehicle for mouth absorption |
| 12/19/2013 | US20130337086 Mineral salt-sulfonic acid compositions and methods of use |
| 12/19/2013 | US20130337076 Particles containing a growth factor, and uses thereof |
| 12/19/2013 | US20130337074 Use of cytokine-releasing, biodegradable particles in hyaluronic acid for the treatment of cartilage defects, in particular of osteoarthrosis |
| 12/19/2013 | US20130337062 Gastro-resistant enzyme pharmaceutical compositions |
| 12/19/2013 | US20130337055 Compositions, methods of treatment and diagnostics for treatment of hepatic steatosis alone or in combination with a hepatitis c virus infection |
| 12/19/2013 | US20130337053 Novel formulations and methods |
| 12/19/2013 | US20130337044 Modulation of effector t cell responses by local depletion of complement component c3 |
| 12/19/2013 | US20130337039 Internalizing ErBB2 Antibodies |
| 12/19/2013 | US20130337038 Chimeric fibronectin matrix mimetics and uses thereof |
| 12/19/2013 | US20130337019 Compositions containing quaternary ammonium compounds |
| 12/19/2013 | US20130337013 Recombinant bacterium comprising a toxin/antitoxin system |
| 12/19/2013 | US20130336990 Enhancement of the action of anti-infective agents and of central and peripheral nervous system agents and transportation of nucleic acid substances |
| 12/19/2013 | US20130336988 Methods for treating early stage or mild neurological disorders |
| 12/19/2013 | US20130336966 Coronin 1 modulators for the treatment of autoimmune and lymphoproliferative disorders and mycobacterial infections |
| 12/19/2013 | US20130336954 Staphylococcal Phage2638A Endolysin Amidase Domain Is Lytic for Staphylococcus aureus |
| 12/19/2013 | US20130336953 Use of creatine kinase for preventing or treating addiction to opiates |
| 12/19/2013 | US20130336952 Pharmaceutical compositions and related methods |
| 12/19/2013 | US20130336950 Material combination for treating inflammatory or infectious diseases |
| 12/19/2013 | US20130336941 Long lasting absorption of flavonoids |
| 12/19/2013 | US20130336927 CULTURING CIRCULAR ssDNA VIRUSES FOR THE PRODUCTION OF VACCINES |
| 12/19/2013 | US20130336923 Carbonic Anhydrase IX (G250) Antibodies and Methods of Use Thereof |
| 12/19/2013 | US20130336904 Novel anti-ageing peptides modulating survivin and compositions including same |
| 12/19/2013 | US20130336903 Personal Care Compositions Comprising a pH Tuneable Gellant and Methods of Using |
| 12/19/2013 | US20130336902 Personal Care Compositions Comprising a Di-Amido Gellant and Methods of Using |
| 12/19/2013 | US20130336893 Exedin-4 Peptide Analogues |
| 12/19/2013 | DE102012011839A1 Interferon-gamma, useful for treating psychiatric disorders including Schizophrenia, cognitive disorders, depression, autism and/or tic disorders of patients |
| 12/19/2013 | CA2876824A1 Nucleic acids for treatment of allergies |
| 12/19/2013 | CA2876668A1 Stable pexiganan formulation |
| 12/19/2013 | CA2876540A1 A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota |
| 12/19/2013 | CA2875449A1 Factor viii sequences |
| 12/18/2013 | EP2674440A2 Multivalent immunoglobulin-based bioactive assemblies |
| 12/18/2013 | EP2674166A1 Use of erythropoietin (EPO) for the local treatment of cancer treatment-associated osteo-necrosis of the jaw |
| 12/18/2013 | EP2674165A2 Hepatocyte growth factor receptor agonist for increasing lymphangiogenesis |
| 12/18/2013 | EP2674164A1 Kallikrein inhibitors and uses thereof |
| 12/18/2013 | EP2674163A1 Skin collagen production promoter |
| 12/18/2013 | EP2674033A1 Process for producing a composition containing active follistatin |
| 12/18/2013 | EP2673640A2 Detection and removal of misfolded proteins/peptides |
| 12/18/2013 | EP2673365A1 Modified plant defensins useful as anti-pathogenic agents |
| 12/18/2013 | EP2673295A1 Hexapeptide with improved activity in the repair of cellular dna of dermal cells |
| 12/18/2013 | EP2673292A1 Wheat antigens and peptides for diagnosis of wheat induced hypersensitivity |
| 12/18/2013 | EP2673050A1 Plant hsp70 for use in the treatment of food allergy |
| 12/18/2013 | EP2673020A1 Dual drug pen-injection device with micro-reservoirs carrying secondary drug for emergency injection |
| 12/18/2013 | EP2672989A1 Immunogenic composition comprising alpha-hemolysin oligopeptides |
| 12/18/2013 | EP2672987A1 Use of creatine kinase for preventing or treating addiction to opiates |
| 12/18/2013 | EP2672986A2 Lyophilized formulations |
| 12/18/2013 | EP2672985A1 Citrate free pharmaceutical compositions comprising anakinra |
| 12/18/2013 | EP2672984A1 Novel prongf mutants and uses thereof in the production of beta-ngf |
| 12/18/2013 | EP2672983A1 Compositions and methods for improving prognosis of a human with subarachnoid hemorrhage |
| 12/18/2013 | EP2672982A2 Ghrelin mimetic polypeptide hapten immunoconjugates having improved solubility and immunogenicity and methods of use thereof |
| 12/18/2013 | EP2672958A1 Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia |
| 12/18/2013 | EP2451474B1 Codon-optimized factor viii variants and synthetic liver-specific promoter |
| 12/18/2013 | EP2344528B1 Pharmaceutical being used for treating cancer and fibrosis disease and the composition and uses thereof |
| 12/18/2013 | EP2310018B1 Use of nifurtimox for treating giardiasis |
| 12/18/2013 | EP2246362B1 Polymer conjugates of mutated neublastin |
| 12/18/2013 | EP2182971B1 Compositions comprising human collagen and human elastin and uses thereof |
| 12/18/2013 | EP2165715B1 Therapeutic agent for cancer, and method for treatment of cancer |
| 12/18/2013 | EP2162146B1 Apotransferrin for use in treating bacterial infections as coadjuvants in antibiotic therapy |
| 12/18/2013 | EP2092069B2 Modified soluble fgf receptor fc fusions with improved biological activity |
| 12/18/2013 | EP2032151B1 Combination therapy method and formulation |
| 12/18/2013 | EP2015766B1 Cyclised alpha-conotoxin vc1.1 for use in the oral treatment of pain |
| 12/18/2013 | EP2007370B1 Novel composition for tumor growth control |
| 12/18/2013 | EP1827485B1 Compositions for preventing, reducing or treating keratinocyte-mediated inflammation |
| 12/18/2013 | EP1782800B1 Methods for detecting JAK3 inhibitors |
| 12/18/2013 | EP1656952B1 Polyalkylene glycol conjugates of interferon beta-1A and uses thereof |
| 12/18/2013 | EP1613272B1 Method for preparation of site-specific protein conjugates |
| 12/18/2013 | EP1606407B1 Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure |
| 12/18/2013 | EP1507791B1 Antisense antiviral agent and method for treating ssrna viral infection |
| 12/18/2013 | EP0647275B2 Cloning and expression of gonadotropin-releasing hormone receptor |
| 12/18/2013 | CN103460042A Use of glu-tubulin as biomarker of drug response to furazanobenzimidazoles |